Atea Pharmaceuticals Inc
AVIR3.170USD
+0.030+0.96%
Close 12/22, 16:00（ET）Quotes delayed by 15 min
247.66MMarket Cap
LossP/E TTM
More Details of Atea Pharmaceuticals Inc Company
Atea Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing oral antiviral therapies to address the unmet medical needs of patients with serious viral infections. The Company has built a proprietary nucleos(t)ide prodrug platform to develop product candidates to treat single-stranded ribonucleic acid (ssRNA) viruses, which are a prevalent cause of serious viral diseases. The Company’s lead program and focus is on the development of the regimen of bemnifosbuvir, a nucleotide analog polymerase inhibitor, and ruzasvir, an investigational, potent, small-molecule inhibitor of hepatitis C virus (HCV) non-structural protein 5A (NS5A), an essential protein for HCV replication. Bemnifosbuvir is an investigational, orally administered guanosine nucleotide double prodrug which targets the HCV non-structural protein 5B (NS5B) RNA-dependent RNA polymerase and inhibits HCV replication.
Atea Pharmaceuticals Inc Info
Ticker SymbolAVIR
Company nameAtea Pharmaceuticals Inc
IPO dateOct 30, 2020
CEOSommadossi (Jean-Pierre)
Number of employees56
Security typeOrdinary Share
Fiscal year-endOct 30
Address225 Franklin Street
CityBOSTON
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code02110
Phone18572048109
Websitehttps://ateapharma.com/
Ticker SymbolAVIR
IPO dateOct 30, 2020
CEOSommadossi (Jean-Pierre)
Company Executives of Atea Pharmaceuticals Inc
Name
Name/Position
Position
Shareholding
Change
Ms. Andrea J. Corcoran, J.D.
Ms. Andrea J. Corcoran, J.D.
Chief Financial Officer, Executive Vice President, Legal, and Secretary
Chief Financial Officer, Executive Vice President, Legal, and Secretary
717.31K
+1.18%
Dr. Jean-Pierre Sommadossi, Ph.D.
Dr. Jean-Pierre Sommadossi, Ph.D.
Chairman of the Board, President, Chief Executive Officer, Founder
Chairman of the Board, President, Chief Executive Officer, Founder
300.94K
--
Mr. John Vavricka
Mr. John Vavricka
Chief Commercial Officer
Chief Commercial Officer
134.59K
--
Mr. Bruno Lucidi
Mr. Bruno Lucidi
Independent Director
Independent Director
112.75K
+35.60%
Dr. Bruce Polsky, M.D.
Dr. Bruce Polsky, M.D.
Independent Director
Independent Director
95.21K
+45.12%
Dr. Polly A. Murphy, DVM, Ph.D.
Dr. Polly A. Murphy, DVM, Ph.D.
Independent Director
Independent Director
86.05K
+52.44%
Dr. Maria Arantxa Horga, M.D.
Dr. Maria Arantxa Horga, M.D.
Chief Medical Officer
Chief Medical Officer
60.88K
--
Mr. Arthur S. Kirsch
Mr. Arthur S. Kirsch
Independent Director
Independent Director
45.71K
+28.00%
Dr. Howard Berman, Ph.D.
Dr. Howard Berman, Ph.D.
Independent Director
Independent Director
--
--
Dr. Janet Hammond, M.D., Ph.D.
Dr. Janet Hammond, M.D., Ph.D.
Chief Development Officer
Chief Development Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Ms. Andrea J. Corcoran, J.D.
Ms. Andrea J. Corcoran, J.D.
Chief Financial Officer, Executive Vice President, Legal, and Secretary
Chief Financial Officer, Executive Vice President, Legal, and Secretary
717.31K
+1.18%
Dr. Jean-Pierre Sommadossi, Ph.D.
Dr. Jean-Pierre Sommadossi, Ph.D.
Chairman of the Board, President, Chief Executive Officer, Founder
Chairman of the Board, President, Chief Executive Officer, Founder
300.94K
--
Mr. John Vavricka
Mr. John Vavricka
Chief Commercial Officer
Chief Commercial Officer
134.59K
--
Mr. Bruno Lucidi
Mr. Bruno Lucidi
Independent Director
Independent Director
112.75K
+35.60%
Dr. Bruce Polsky, M.D.
Dr. Bruce Polsky, M.D.
Independent Director
Independent Director
95.21K
+45.12%
Dr. Polly A. Murphy, DVM, Ph.D.
Dr. Polly A. Murphy, DVM, Ph.D.
Independent Director
Independent Director
86.05K
+52.44%
Revenue Breakdown
FY2022
FY2021
FY2020
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
United States
0.00
0.00%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
BML Capital Management LLC
9.57%
BlackRock Institutional Trust Company, N.A.
7.95%
JPM Partner LLC
7.51%
Fidelity Management & Research Company LLC
7.45%
Tang Capital Management, LLC
6.18%
Other
61.35%
Shareholders
Shareholders
Proportion
BML Capital Management LLC
9.57%
BlackRock Institutional Trust Company, N.A.
7.95%
JPM Partner LLC
7.51%
Fidelity Management & Research Company LLC
7.45%
Tang Capital Management, LLC
6.18%
Other
61.35%
Shareholder Types
Shareholders
Proportion
Investment Advisor
41.46%
Investment Advisor/Hedge Fund
14.08%
Hedge Fund
11.46%
Corporation
7.51%
Individual Investor
5.41%
Family Office
4.33%
Research Firm
1.52%
Pension Fund
0.36%
Bank and Trust
0.16%
Other
13.72%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
229
54.23M
76.18%
+39.26K
2025Q3
245
54.19M
76.92%
+471.68K
2025Q2
254
54.98M
75.58%
-215.33K
2025Q1
284
55.18M
77.35%
-10.98M
2024Q4
300
58.43M
81.38%
-1.55M
2024Q3
302
59.81M
81.33%
+1.04M
2024Q2
304
58.76M
78.90%
+2.36M
2024Q1
313
56.24M
78.49%
-9.83M
2023Q4
332
56.80M
79.92%
-987.94K
2023Q3
366
57.29M
93.59%
+1.19M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
BML Capital Management LLC
7.61M
9.59%
--
--
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
6.38M
8.04%
-272.13K
-4.09%
Jun 30, 2025
JPM Partner LLC
5.87M
7.39%
--
--
Apr 22, 2025
Fidelity Management & Research Company LLC
5.72M
7.21%
-298.26K
-4.96%
Jun 30, 2025
Tang Capital Management, LLC
4.89M
6.16%
+89.20K
+1.86%
Jun 30, 2025
The Vanguard Group, Inc.
4.89M
6.16%
+159.52K
+3.37%
Jun 30, 2025
Radoff Family Foundation
3.38M
4.26%
+275.00K
+8.86%
Apr 16, 2025
Bain Capital Life Sciences Investors, LLC
2.49M
3.13%
--
--
Jun 30, 2025
Geode Capital Management, L.L.C.
1.93M
2.43%
-51.76K
-2.62%
Jun 30, 2025
State Street Investment Management (US)
1.78M
2.24%
+5.71K
+0.32%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
ALPS Medical Breakthroughs ETF
0.1%
iShares Micro-Cap ETF
0.05%
ProShares Ultra Nasdaq Biotechnology
0.03%
Avantis US Small Cap Equity ETF
0.03%
iShares Russell 2000 Value ETF
0.02%
Invesco Nasdaq Biotechnology ETF
0.02%
iShares Biotechnology ETF
0.02%
Schwab U.S. Small-Cap ETF
0.01%
Global X Russell 2000 ETF
0.01%
ProShares Hedge Replication ETF
0.01%
View more
ALPS Medical Breakthroughs ETF
Proportion0.1%
iShares Micro-Cap ETF
Proportion0.05%
ProShares Ultra Nasdaq Biotechnology
Proportion0.03%
Avantis US Small Cap Equity ETF
Proportion0.03%
iShares Russell 2000 Value ETF
Proportion0.02%
Invesco Nasdaq Biotechnology ETF
Proportion0.02%
iShares Biotechnology ETF
Proportion0.02%
Schwab U.S. Small-Cap ETF
Proportion0.01%
Global X Russell 2000 ETF
Proportion0.01%
ProShares Hedge Replication ETF
Proportion0.01%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Atea Pharmaceuticals Inc?
The top five shareholders of Atea Pharmaceuticals Inc are:
BML Capital Management LLC holds 7.61M shares, accounting for 9.59% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 6.38M shares, accounting for 8.04% of the total shares.
JPM Partner LLC holds 5.87M shares, accounting for 7.39% of the total shares.
Fidelity Management & Research Company LLC holds 5.72M shares, accounting for 7.21% of the total shares.
Tang Capital Management, LLC holds 4.89M shares, accounting for 6.16% of the total shares.
BML Capital Management LLC holds 7.61M shares, accounting for 9.59% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 6.38M shares, accounting for 8.04% of the total shares.
JPM Partner LLC holds 5.87M shares, accounting for 7.39% of the total shares.
Fidelity Management & Research Company LLC holds 5.72M shares, accounting for 7.21% of the total shares.
Tang Capital Management, LLC holds 4.89M shares, accounting for 6.16% of the total shares.
What are the top three shareholder types of Atea Pharmaceuticals Inc?
The top three shareholder types of Atea Pharmaceuticals Inc are:
BML Capital Management LLC
BlackRock Institutional Trust Company, N.A.
JPM Partner LLC
BML Capital Management LLC
BlackRock Institutional Trust Company, N.A.
JPM Partner LLC
How many institutions hold shares of Atea Pharmaceuticals Inc (AVIR)?
As of 2025Q4, 229 institutions hold shares of Atea Pharmaceuticals Inc, with a combined market value of approximately 54.23M, accounting for 76.18% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -0.74%.
What is the biggest source of revenue for Atea Pharmaceuticals Inc?
In FY2022, the -- business generated the highest revenue for Atea Pharmaceuticals Inc, amounting to -- and accounting for --% of total revenue.
